J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
You may also be interested in...
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
A two-day joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is scheduled for Jan. 13-14, 2005